Phaseline

Companies › ITB-Med

ITB-Med: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Jun 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Siplizumab (TCD601)
T-cell surface antigen CD2 inhibitor
CD2Phase 2Liver TransplantationJun 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06019507Siplizumab (TCD601)Phase 2Liver TransplantationOtherJun 2029

Targets

CD2 (1)

Companies with the same targets

Nefro Avillion Clinical Development

Companies built like this

Rebel Medicine Corza Medical Angitia Zynerba Pharmaceuticals Serum Life Science Europe

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.